Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics (Nasdaq: GRCE) rebranded from Acasti Pharma and refocused on rare disease drug reformulations using the 505(b)(2) pathway. Its lead candidate, GTx-104 (injectable nimodipine for aSAH), delivered positive Phase 3 STRIVE-ON results, reducing hypotension events, improving dose int...